Abstract
With the advent of highly active antiretroviral therapy (HAART), the reduction in overall mortality and morbidity in HIV patients has been accompanied by the emergence of liver disease as a leading cause of death. Elevated liver enzymes may be due to HAART or to other risk factors, including hepatitis co-infection and alcohol use. The different components of HAART are each associated with different risks of liver toxicity. Most drugs are metabolized by cytochrome P450 enzymes in the liver, and this may be affected by liver disease. The mechanisms for drug-induced liver injury include dose-dependent toxicity, hypersensitivity reactions, idiosyncratic reactions, mitochondrial toxicity, and immune reconstitution. The diagnosis of drug-induced liver injury is exclusionary. Once diagnosed, management generally involves discontinuation of the offending drug(s). A number of studies in progress are investigating whether treatment of hepatitis co-infection can improve the tolerability of HAART.
Keywords: Highly active antiretroviral therapy, liver injury, hepatitis co-infection
Current Drug Safety
Title: Highly Active Antiretroviral Therapy-Induced Liver Injury
Volume: 3 Issue: 1
Author(s): Maurizio Bonacini and Ira Inductivo-Yu
Affiliation:
Keywords: Highly active antiretroviral therapy, liver injury, hepatitis co-infection
Abstract: With the advent of highly active antiretroviral therapy (HAART), the reduction in overall mortality and morbidity in HIV patients has been accompanied by the emergence of liver disease as a leading cause of death. Elevated liver enzymes may be due to HAART or to other risk factors, including hepatitis co-infection and alcohol use. The different components of HAART are each associated with different risks of liver toxicity. Most drugs are metabolized by cytochrome P450 enzymes in the liver, and this may be affected by liver disease. The mechanisms for drug-induced liver injury include dose-dependent toxicity, hypersensitivity reactions, idiosyncratic reactions, mitochondrial toxicity, and immune reconstitution. The diagnosis of drug-induced liver injury is exclusionary. Once diagnosed, management generally involves discontinuation of the offending drug(s). A number of studies in progress are investigating whether treatment of hepatitis co-infection can improve the tolerability of HAART.
Export Options
About this article
Cite this article as:
Bonacini Maurizio and Inductivo-Yu Ira, Highly Active Antiretroviral Therapy-Induced Liver Injury, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783333916
DOI https://dx.doi.org/10.2174/157488608783333916 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews Inhibition of Voltage-Gated Calcium Channels by RGK Proteins
Current Molecular Pharmacology Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Safety of Herbal Medicines Use: Case Study of Ikorodu Residents in Lagos, Nigeria
Current Drug Safety Brain Perfusion In Sepsis
Current Vascular Pharmacology Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Pathophysiological Insights into Atrial Fibrillation Following Cardiac Surgery: Implications for Current Pharmaceutical Design
Current Pharmaceutical Design Neurohormonal Activation in Ischemic Stroke: Effects of Acute Phase Disturbances on Long-Term Mortality
Current Neurovascular Research Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology
Current Pharmaceutical Biotechnology In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Artificial Neural Networks for the Prediction of Response to Interferon Plus Ribavirin Treatment in Patients with Chronic Hepatitis C
Current Pharmaceutical Design